OptimizeRx (NASDAQ:OPRX – Get Free Report) and OneMedNet (NASDAQ:ONMD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Risk & Volatility
OptimizeRx has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, OneMedNet has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Insider and Institutional Ownership
76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 0.9% of OneMedNet shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by company insiders. Comparatively, 50.2% of OneMedNet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares OptimizeRx and OneMedNet’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OptimizeRx | 5.33% | 9.58% | 7.47% |
| OneMedNet | -584.20% | N/A | -521.20% |
Earnings & Valuation
This table compares OptimizeRx and OneMedNet”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OptimizeRx | $109.43 million | 1.19 | $5.13 million | $0.25 | 27.76 |
| OneMedNet | $1.46 million | 20.52 | -$2.80 million | ($1.60) | -3.15 |
OptimizeRx has higher revenue and earnings than OneMedNet. OneMedNet is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for OptimizeRx and OneMedNet, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OptimizeRx | 1 | 2 | 6 | 0 | 2.56 |
| OneMedNet | 1 | 0 | 0 | 0 | 1.00 |
OptimizeRx currently has a consensus target price of $11.21, suggesting a potential upside of 61.59%. Given OptimizeRx’s stronger consensus rating and higher possible upside, equities research analysts clearly believe OptimizeRx is more favorable than OneMedNet.
Summary
OptimizeRx beats OneMedNet on 11 of the 14 factors compared between the two stocks.
About OptimizeRx
OptimizeRx is a healthcare technology company that connects life sciences companies with healthcare professionals and patients through digital communications. Its platform uses channels such as electronic health records and other clinical workflows to deliver relevant information at the point of care. The company’s services support programs for medication access and affordability, patient education and engagement, and communication between healthcare providers and life sciences organizations. OptimizeRx also provides tools intended to help life sciences companies reach clinicians and patients through digital channels.
About OneMedNet
OneMedNet Corporation provides real-world data (RWD) for healthcare research. Through its iRWD platform, the company helps connect healthcare organizations that contribute medical information with pharmaceutical, biotechnology and medical-device companies seeking data for research and product development. Its offerings include curated, de-identified clinical records and medical imaging data. These datasets can support activities such as clinical research and the evaluation of medicines and medical devices, while the platform is designed to facilitate secure data access and collaboration.
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
